

# RAUCON *BD Executive News*

Vol. 16 # 3 | 20 February 2020

## Hot Company News

\* Acquisition: **Dermapharm Holding SE** signed a contract via **Dermapharm Beteiligungs GmbH** to acquire **Allergopharma GmbH & Co. KG**, based in Reinbek near Hamburg, Germany, a subsidiary of Merck KGaA, Darmstadt, Germany. 19 Feb 2020 ([www.allergopharma.de](http://www.allergopharma.de))

\* Acquisition: **BetterLife Pharma Inc.** acquired Swiss based **Solmic AG** with its IP portfolio including unique formulation technology for the production of stable micelles containing water insoluble compounds such as CBD. Solmic AG's unique micelle production technology has been shown to greatly enhance the bioavailability of fat soluble ingredients by as much as 15 times. This technology allows for accelerated uptake of cannabinoids in the human digestive tract. A unique Solmic micelle 1% CBD formulation is currently sold in the European market. 3 Feb 2020 ([abetterlifepharma.com](http://abetterlifepharma.com))

\* Acquisition: **Catalent, Inc.** had completed its acquisition of **MaSTherCell Global Inc.**, positioning Catalent as a technology, development and manufacturing partner for innovators of advanced biotherapeutics. 10 Feb 2020 ([www.catalent.com](http://www.catalent.com))

\* Acquisition: **CODA Biotherapeutics, Inc.**, a preclinical-stage biopharmaceutical company developing a gene therapy-mediated chemogenetic platform, today announced it has completed the acquisition of **Attenua, Inc.** Terms are not being disclosed. 5 Feb 2020 ([www.codabiotherapeutics.com](http://www.codabiotherapeutics.com))

\* Commercialization: **Knight Therapeutics Inc.**, and **Debiopharm** have entered into an exclusive agreement that grants Knight the rights to commercialize Trelstar® (triptorelin) in Canada. Knight expects to take over commercial activities from Debiopharm's cur-

rent partner Allergan and begin recording revenues in early 2020. Previously, Trelstar® was successfully launched and commercialized in Canada by **Paladin Labs Inc.** between 2006 to 2014. 9 Jan 2020 ([www.debiopharm.com](http://www.debiopharm.com))

\* Acquisition: **ICON plc** has acquired **MedPass International**, the leading European medical device CRO, regulatory and reimbursement consultancy, that specialises in medical device development and market access. 19 Feb 2020 ([www.iconplc.com/](http://www.iconplc.com/))

\* Name change: **Integrated Cannabis Company, Inc.**, a multi-state brand operator in California and Nevada, announced that, pursuant to a directors' resolution, it will change its name to **Icanic Brands Company Inc.** 13 Feb 2020 ([www.icaninc.com](http://www.icaninc.com))

\* License Agreement: **Karyopharm Therapeutics Inc.**, an oncology-focused pharmaceutical company, and **Promedico**, a member of the **Neopharm Group**, announced their entry into an exclusive distribution agreement for the commercialization of XPOVIO® (selinexor), Karyopharm's lead SINE compound, in Israel and the Palestinian Authority. Karyopharm will receive certain prespecified payments and is eligible to receive additional payments if prespecified regulatory and commercial milestones are achieved by Promedico. 11 Feb 2020 ([www.karyopharm.com](http://www.karyopharm.com))

\* Distribution: euroPLX attendee **Luye Pharma Group Ltd.** has entered into an exclusive distribution and marketing service agreement with **Cipla Medpro South Africa (Pty) Limited**, for Seroquel® and Seroquel XR® in South Africa, Namibia and Botswana. Cipla Medpro is a wholly-owned subsidiary of **Cipla Limited, India**, a global pharmaceutical company. 11 Feb 2020 ([www.luye-pharm.com](http://www.luye-pharm.com))

\* Licensing: **Norgine B.V.** announced a number of deals for the commercialisation of Norgine's product PLENVU® (a lower-volume (1L) polyethylene glycol (PEG) based bowel preparation for colonoscopy in adults) around the world. Norgine entered into exclusive licence and distribution agreements with:

- **Faes Farma S.A.** in Chile, Colombia, Costa Rica, Dominican Republic, Ecuador, El Salvador, Guatemala, Honduras, Mexico, Nicaragua, Panama and Peru.
- **Pharmacare Limited T/A Aspen Pharmacare** in the Republic of Southern Africa, Lesotho, Eswatini, Botswana and Namibia.
- **Swixx Biopharma** in Central and Eastern Europe including Bosnia and Herzegovina, Bulgaria, Croatia, Czech Republic, Hungary, Kosovo, Montenegro, North Macedonia, Poland, Romania, Serbia, Slovakia, and Slovenia. 12 Feb 2020 ([www.norgine.com](http://www.norgine.com))

\* Acquisition: **PCI Pharma Services** announced the acquisition of **Bellwyck Pharma Services**, headquartered in Toronto, Canada. With 25 years of experience, Bellwyck is a leader in primary and secondary packaging and labeling for clinical trial and commercial drug markets. 11 Feb 2020 ([/pciservices.com](http://pciservices.com))

\* Acquisition: **Promedior, Inc.** completed its previously announced sale to **Roche**. With this acquisition, Roche obtained full rights to Promedior's entire portfolio of molecules for serious fibrotic diseases, notably PRM-151. Under the terms of the merger agreement, Roche made an upfront cash payment of USD 390 million, with additional contingent payments of up to USD 1 billion to be made based on the achievement of certain predetermined development, regulatory and commercial milestones. 13 Feb 2020 ([promedior.com](http://promedior.com))

## BD People on the Move

\* Centrient Pharmaceuticals: **Patrick Tichy**, who has been Head of Licensing & Sales, has left the company. Mr. Tichy is a RauCon Bell Club Member. (Pers Comm 10 Feb 2020)

\* Dr. Max Pharma Limited: euroPLX attendee **Tomas Orlovsky**, who has been sourcing specialist left the company. (Pers Comm 7 Feb 2020)

\* Dr. Reddy's Laboratories Ltd.: **Subir Kohli**, who has been Head of Out-Licensing for Dr. Reddy's Laboratories (UK) Ltd, and a frequent euroPLX attendee, has left the company. (Pers Comm 7 Feb 2020)

\* IPCA Laboratories Ltd: **Manish Venkatachalapathy**, who has been Deputy General Manager for Business Development & Licensing, left the company. (Corp Comm 11 Feb 2020)

\* Laboratorios Alter S.A.: **Lucia Morillo** who has been Business Development Manager and euroPLX attendee, left the company in February. (Pers Comm 9 Feb 2020)

\* Montefarmaco: Frequent euroPLX attendee **Ariella Annoni**, who has been R&D Manager, left Montefarmaco in order to explore other professional opportunities on 31 January. (Pers Comm 31 Jan 2020)